LUNG - MCAP CO - Pulmonx Corporation

The available price action for Pulmonx Corporation (LUNG) reflects the dynamics of the company producing emphysema therapy devices. The current indicator stands at 0.08. Business growth is driven by the popularity of the Zephyr system and the expansion of insurance reimbursements. Stringent FDA requirements and patent protection create a robust barrier to entry for competitors. An impeccable brand image among pulmonologists guarantees steady demand for innovative solutions.

The expansion of the Zephyr system for emphysema therapy is directly reflected in the current market capitalization of Pulmonx Corporation (LUNG). This metric aggregates the total business value, allowing for an assessment of the corporation's scale in the eyes of investors. The calculation is based on the product of the market price per share and the total number of outstanding shares. This indicator captures the market consensus regarding ARR growth rates, while the costs of surgeon qualification are already integrated into the final asset value.